The best peptides for sleep, honestly ranked.

Sleep is the peptide category where consumer marketing and published RCT evidence diverge the most — even by grey-market peptide standards. That's the starting frame for the best peptides for sleep conversation. We'll show you what the data actually says.

Sleep is one of the largest single modifiers of healthspan. We get that, and we'd never tell you it doesn't matter. There's real biology underlying peptide interest. The delta-sleep cycle is when GH pulses peak. Pineal melatonin synthesis follows circadian rhythms. The HPA axis (the body's stress-response system) is modulated by sleep architecture.

Peptides intervene at multiple points along these axes. The problem we keep running into: most of the "sleep peptide" field rests on preclinical mechanism plus Russian-language clinical reports that aren't PubMed-indexed. The human RCT evidence for sleep-specific outcomes is meaningfully thinner than the marketing implies.

Here's the irony. The most rigorous recent sleep-relevant trial is actually for oral NMN — not one of the peptides in this article. The 2024 Morifuji et al. trial in GeroScience showed 250 mg/day NMN improved daytime dysfunction and global Pittsburgh Sleep Quality Index scores in older adults (Morifuji et al., 2024). NMN is an oral precursor for a coenzyme, not a peptide. The peptide evidence base for sleep is meaningfully thinner than that.

How "sleep peptides" allegedly work

Four mechanistic stories underlie the peptides we'll rank below.

• Direct sleep induction — the DSIP claim. Remains scientifically unconfirmed.
• Pineal melatonin stimulation — Epithalon's claimed mechanism.
• HPA-axis modulation for stress-driven insomnia — Selank and Semax.
• GH-axis enhancement of slow-wave sleep — CJC-1295 paired with pre-bed dosing.

Each mechanism is biologically plausible. The evidence translating mechanism to sleep-outcome improvement in human RCTs is sparse. We'll show you exactly how sparse, peptide by peptide.

The 2024 review by Mu and colleagues in Frontiers in Pharmacology tested a DSIP fusion peptide (engineered to cross the blood-brain barrier) in a chemically-induced insomnia mouse model. It modulated serotonin, glutamate, dopamine, and melatonin levels. The critical caveat from the authors: the fusion peptide outperformed bare DSIP, suggesting plain DSIP performs less well. That's consistent with the historic concern that DSIP itself crosses the blood-brain barrier poorly.

Here is the ranked five in one view, before we take each in turn.

1. DSIP: the "natural sleep peptide" with unconfirmed mechanism

DSIP (Delta Sleep-Inducing Peptide) is the synthetic nonapeptide isolated in 1977 from rabbit cerebral venous blood collected during electrically-induced sleep. Schoenenberger and Monnier in Switzerland did the foundational work. Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE), 9 amino acids long.

Despite the name, DSIP's status as a true endogenous sleep-inducing peptide has remained contested for nearly 5 decades. There's no validated endogenous DSIP receptor. No demonstration of a physiological role in human sleep regulation has been established.

Recent (2020-2026) preclinical work on DSIP doesn't focus on sleep at all. We checked. A pair of 2021 studies from the Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry showed intranasal DSIP and a structural analog reduced infarct volume in mouse focal-stroke and rat myocardial-infarction models when given during reperfusion (Tukhovskaya et al., 2021a).

The critical safety caveat from those same authors: in pilot studies, administering the peptides during occlusion (rather than reperfusion) resulted in 100% mortality. That makes timing-of-administration critical and raises safety concerns about indiscriminate use.

• Grey-market protocol: 100–200 mcg subcutaneous pre-bed.
• Route: subcutaneous (oral and intranasal also used).
• Cycle: typically nightly for 1–2 weeks, then break.
• Critical caveat: 2021 stroke-model finding showed 100% mortality with mistimed administration.

Strengths. Longest publication history of any "sleep peptide" (since 1977). Real preclinical work in neuroprotection and reperfusion-injury contexts. The 2024 Mu et al. fusion-peptide study showed BBB-engineered DSIP variants produced neurotransmitter modulation in an insomnia mouse model.

Limitations. The signature mechanism (endogenous sleep induction) remains scientifically unconfirmed despite ~50 years of investigation. No validated DSIP receptor has been identified. Russian-language clinical work exists but isn't PubMed-indexed or Western RCT-grade. Native DSIP crosses the blood-brain barrier poorly — recent work focuses on engineered fusion peptides to fix that, which raises basic questions about how unmodified consumer DSIP reaches CNS targets. The timing-dependent toxicity finding (100% mortality with mistimed administration in stroke models) is a concerning signal not addressed in consumer marketing.

2. Epithalon: pineal melatonin synthesis stimulation

Epithalon's sleep-relevant claim is pineal melatonin synthesis stimulation and circadian rhythm modulation. The mechanism story: AEDG (Ala-Glu-Asp-Gly), a 4-residue peptide, is derived from Epithalamin, a bovine pineal extract.

The Khavinson group has reported melatonin synthesis stimulation in pineal-gland cells and modulation of circadian-rhythm genes (CLOCK, Cry2, AANAT, ASMT). The 2024 Russian-language buccal-epithelium study by Ivko and colleagues (PMID 39742404) documented effects on cellular aging markers, including potential melatonin-pathway interactions.

The 2025 review by Araj and colleagues in International Journal of Molecular Sciences summarizes 25 years of Epitalon studies claiming "significant geroprotective and neuroendocrine effects" via antioxidant, neuroprotective, and antimutagenic mechanisms.

• Grey-market sleep protocol: 5–10 mg subcutaneous daily for 10–20 days, repeated every 6 months.
• Route: subcutaneous.
• Sleep-relevant mechanism: pineal melatonin synthesis + circadian rhythm gene modulation.

Strengths. Real mechanistic biology connecting AEDG to pineal-gland melatonin synthesis. Khavinson-group preclinical evidence supports melatonin pathway involvement. The 2025 Brunel telomerase replication confirms the broader pharmacological signal is reproducible by at least one independent Western group.

Limitations. No PubMed-indexed Western randomized controlled trials for sleep or any other indication. The Khavinson single-source dominance is the major methodological concern. Russian-language clinical reports exist but aren't RCT-grade. The cancer-cell ALT activation finding from the 2025 Brunel study adds a theoretical pro-cancer safety concern that isn't specific to sleep use. Cell-culture data on melatonin pathway modulation doesn't establish sleep-outcome improvement in human RCTs.

3. Semax: the AM-dosed HPA-axis modulator

Semax is a synthetic 7-residue analog of ACTH(4-10) (sequence Met-Glu-His-Phe-Pro-Gly-Pro, N-acetylated). Russian preclinical literature documents BDNF and NGF upregulation, dopaminergic and serotonergic modulation, and improved cognitive performance in stress-resilience models. It's approved in Russia under the Russian regulatory framework.

The sleep-relevant mechanism is indirect. Semax modulates the HPA axis. Dosed in the morning, it may help normalize circadian cortisol patterns that drive stress-related sleep dysfunction.

Here's the framing you need. Semax isn't a sleep peptide in the direct-sleep-induction sense. Its sleep-relevant use is downstream of stress-axis modulation. And only when you dose it in the morning to support natural cortisol rhythm. Evening dosing could disrupt sleep onset.

• Grey-market protocol: 250–500 mcg intranasal in the morning.
• Route: intranasal (with proprietary stabilization in the Russian-approved formulation).
• Sleep-relevant timing: AM dosing only — evening dosing could disrupt sleep.

Strengths. Approved in Russia with substantial Russian-language clinical history. Real BDNF and NGF upregulation in preclinical models. Mechanistically distinct from direct sleep-induction peptides — it addresses stress-driven insomnia rather than sleep mechanics. The 2026 review by Mavrych and colleagues in Frontiers in Aging positions Semax within the broader gerontology peptide landscape.

Limitations. No PubMed-indexed Western randomized controlled trials for sleep, anxiety, or cognitive enhancement. Russian-approved indication is for stroke recovery and cognitive disorders, not sleep specifically. The sleep-relevant use case is downstream of stress-axis modulation. Evening dosing could disrupt sleep onset by raising activating neurotransmitters at the wrong time of day.

DSIP

Sleep / Neuropeptide

Nonapeptide 9 aa Cerebral venous origin

The same compound cited across the preclinical neurotransmitter-modulation studies in this review. Lab-verified identity and purity.

Shop DSIP

4. Selank: the anxiolytic for sleep onset

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro, N-acetylated) — a tuftsin analog with a C-terminal Pro-Gly-Pro extension to enhance stability. It's been approved in Russia for clinical use as an anxiolytic since 2009, marketed for generalized anxiety disorder.

Russian preclinical literature documents reduction of anxiety-like behavior, IL-6 modulation, and stabilizing effects on serotonergic and dopaminergic pathways. Critically, all without the sedation or withdrawal seen with classical anxiolytics like benzodiazepines.

The sleep-relevant use case is sleep-onset anxiety. If your sleep difficulties stem from racing thoughts, anxiety-driven hyperarousal, or stress-related autonomic activation, Selank's mechanism is conceptually different from sedating sleep aids: it doesn't induce sleep directly. It reduces the anxiety obstacle to falling asleep naturally.

• Grey-market protocol: 250–500 mcg intranasal 30–60 minutes before bed.
• Route: intranasal (Russian-approved formulation).
• Use case: anxiety-driven sleep onset, not sleep maintenance.

Strengths. Approved in Russia for anxiety since 2009, with substantial Russian-language clinical history. Mechanism distinct from sedating sleep aids — reduces anxiety without producing sedation, tolerance, or withdrawal. Conceptually appropriate for sleep-onset insomnia driven by anxiety rather than circadian disruption or sleep mechanics.

Limitations. No PubMed-indexed Western randomized controlled trials for sleep, anxiety, or any other indication. Russian-approved indication is for anxiety, not sleep specifically. The sleep-relevant use is anxiety-mediated, not direct sleep induction. Russian-language clinical evidence isn't Western RCT-grade.

5. CJC-1295: the GH-axis deep-sleep enhancer

CJC-1295 lands on this list as a deep-sleep enhancer rather than a direct sleep peptide. The mechanism story: endogenous growth hormone secretion peaks during the first slow-wave-sleep cycle of the night. GH-axis peptides timed pre-bed can amplify that pulse.

Whether this translates to subjectively better sleep quality is uncharacterized in controlled human trials. Our read: the mechanism is reasonable but the outcome data isn't there.

The 2020 review by Sinha and colleagues in Translational Andrology and Urology discusses CJC-1295's role in pulsatile GH stimulation — relevant for body-composition contexts and theoretically relevant for slow-wave sleep enhancement. The 2026 review by Mendias and Awan in Sports Medicine concludes robust human clinical evidence for performance, body composition, or musculoskeletal recovery indications is essentially absent. The sleep claim is a similar evidence-gap inference.

• Grey-market sleep protocol: CJC-1295 100–200 mcg + Ipamorelin 200–300 mcg subcutaneous pre-bed.
• Mechanism story: amplifies endogenous overnight GH pulse during slow-wave sleep cycle.
• Direct sleep evidence: none in published RCTs.

Strengths. Mechanism is reasonable. Endogenous GH peaks during the first slow-wave-sleep cycle, and GH-axis peptides amplify that pulse. Pulsatile GH release pattern is preserved, unlike exogenous recombinant GH. Cleanest selectivity profile of the GHRP family when paired with ipamorelin.

Limitations. No published RCTs of CJC-1295 (alone or paired) for sleep quality, sleep architecture, or insomnia outcomes. The mechanism story is plausible but the actual sleep-outcome benefit is uncharacterized. WADA-prohibited (S2) for both compounds with reliable detection. Clinical development of CJC-1295 was discontinued years ago. Standard GH-axis side effects (edema, joint pain, insulin resistance) apply.

Adjacent / support peptides

Oral NMN: the sleep-PSQI evidence option

The 2024 Morifuji et al. trial in GeroScience showed 250 mg/day oral NMN for 12 weeks improved daytime dysfunction and global PSQI scores in older adults (Morifuji et al., 2024).

NMN isn't a peptide. It's a NAD+ precursor. But it has the most rigorous published RCT evidence for sleep-quality outcomes of any compound discussed alongside the "sleep peptide" category. If you're looking for actual published RCT support for a sleep-improvement intervention, oral NMN is the better-evidenced option.

Tesamorelin and Ipamorelin: the GH-axis adjuncts

Same GH-axis-amplifies-slow-wave-sleep story as CJC-1295, with different mechanisms and evidence bases. Tesamorelin is FDA-approved (HIV lipodystrophy) with the deepest RCT evidence in the GH-axis category. Ipamorelin has the cleanest selectivity profile. Neither has published RCT evidence for sleep-specific outcomes.

Optimal stacking protocols

The pre-bed sleep protocol (anxiety-mediated)

Selank intranasal 30–60 minutes pre-bed, paired with a sleep-hygiene foundation: cool bedroom, blue-light reduction, consistent schedule. The Selank addresses sleep-onset anxiety without sedation. The lifestyle foundation addresses the substrate. This protocol uses the mechanism (anxiolytic without sedation) most appropriate for sleep-onset insomnia driven by anxiety.

The GH-axis deep-sleep stack

CJC-1295 100–200 mcg + Ipamorelin 200–300 mcg subcutaneous immediately pre-bed. Mechanism: amplify endogenous GH pulse during first slow-wave-sleep cycle. Sleep-outcome evidence is mechanism-inferred, not RCT-validated. This is the most commonly-used grey-market sleep stack despite the absence of published sleep-outcome RCTs.

The cyclical pineal protocol

Epithalon 5–10 mg subcutaneous daily for 10–20 days every 6 months, based on Khavinson clinical practice. Mechanism: pineal melatonin synthesis stimulation + circadian-rhythm gene modulation. Evidence: Khavinson-group preclinical work plus Russian-language non-RCT clinical reports. No Western RCT validation. The theoretical cancer-cell ALT activation concern from the 2025 Brunel study applies.

Training, nutrition, and lifestyle

If you only fix one thing about your sleep, fix this layer first. Sleep is responsive to lifestyle interventions with stronger evidence than any peptide on this list. Sleep hygiene (consistent schedule, cool dark bedroom, blue-light reduction, caffeine timing), cognitive behavioral therapy for insomnia (CBT-I), and standard FDA-approved interventions (melatonin, prescription hypnotics where clinically indicated) all have substantially stronger published evidence bases.

Caffeine timing is the largest single dietary modifier of sleep onset latency and sleep architecture. Caffeine's half-life is ~5 hours, with substantial individual variation. Afternoon caffeine routinely disrupts sleep onset and slow-wave architecture in controlled trials.

Light exposure timing matters. Morning bright-light exposure entrains circadian rhythm. Evening bright or blue light delays melatonin release and pushes sleep onset later. If you fix nothing else about your sleep stack, fix your light exposure.

Epithalon

Khavinson / Longevity

50 mg ≥99% pure AEDG tetrapeptide

Synthetic AEDG tetrapeptide derived from Epithalamin. The same reference compound used across the cited Khavinson and 2025 Brunel telomerase studies. COA available with each lot.

Learn more

Safety, monitoring, and legal status

Required monitoring

For DSIP, Epithalon, Semax, and Selank, there's limited validated monitoring framework in people. Baseline mental-health assessment and sleep-quality assessment with validated instruments (Pittsburgh Sleep Quality Index, Insomnia Severity Index) before treatment is the cleanest framework. That way you can track whether peptide use coincides with measurable sleep improvement.

For CJC-1295 + Ipamorelin: standard GH-axis monitoring (IGF-1, fasting glucose, lipid panel).

Known risks

The DSIP timing-dependent toxicity finding from 2021 stroke models is concerning: 100% mortality in animal models when administered during ischemic occlusion rather than reperfusion. Epithalon's cancer-cell ALT activation from the 2025 Brunel study applies to chronic use. Drug interactions with sedative-hypnotics, melatonin, and antidepressants are theoretically concerning but unstudied for the unapproved peptides. Manufacturing variance and contamination risks for grey-market product are documented hazards.

Legal and regulatory

None of the peptides on this list are FDA-approved for sleep, insomnia, or any other indication. Selank and Semax are approved in Russia under the Russian regulatory framework. Selank is approved for anxiety. Semax is approved for stroke recovery and cognitive disorders. Epithalon has Russian clinical history. DSIP has neither US nor formal Russian therapeutic approval. CJC-1295 is WADA-prohibited under S2.

Frequently asked questions

Does DSIP actually help you sleep? The signature sleep-induction mechanism has remained scientifically unconfirmed for nearly 50 years. No validated DSIP receptor has been identified, and the central claim isn't robustly supported in modern human literature. Recent preclinical work focuses on stroke and cardiac reperfusion injury, not sleep. Russian-language clinical work exists but isn't PubMed-indexed or RCT-grade.

What's the strongest peptide-related sleep evidence? Strictly speaking, none of the peptides on this list. The strongest sleep-related evidence in the broader peptide / coenzyme space is for oral NMN. The 2024 Morifuji et al. trial in GeroScience showed 250 mg/day NMN improved daytime dysfunction and global PSQI scores in older adults. NMN is a NAD+ precursor, not a peptide.

Why do people use Epithalon for sleep? The mechanism story is pineal melatonin synthesis stimulation and circadian-rhythm gene modulation, derived from AEDG's origin in Epithalamin (bovine pineal extract). Khavinson-group preclinical work supports melatonin pathway involvement. No PubMed-indexed Western RCT validates Epithalon for sleep specifically.

When should I dose Semax for sleep? In the morning, not the evening. Semax modulates BDNF, NGF, and dopaminergic / serotonergic pathways. Evening dosing risks activating arousal systems at the wrong time of day. The sleep-relevant use is normalizing morning cortisol patterns to reduce stress-driven sleep dysfunction.

Can Selank help with insomnia? The sleep-relevant use is sleep-onset insomnia driven by anxiety. Selank is approved in Russia as an anxiolytic without sedation, tolerance, or withdrawal. That makes it conceptually appropriate for anxiety-mediated sleep onset. No Western RCT validates the sleep use case directly.

Does CJC-1295 improve deep sleep? The mechanism story is amplifying the endogenous GH pulse that peaks during the first slow-wave-sleep cycle. Whether this translates to subjectively better sleep quality is uncharacterized in published RCTs. No published trials of CJC-1295 for sleep-specific outcomes exist.

Are sleep peptides safer than prescription sleep aids? No published evidence supports this claim. Prescription hypnotics have extensive safety data from RCTs and post-marketing surveillance. Sleep peptides have meaningfully thinner safety data, manufacturing variance concerns, and (for DSIP specifically) a documented timing-dependent toxicity signal from the 2021 stroke models.

What should I try first for sleep problems? Standard first-line interventions have substantially stronger evidence than peptides. Sleep hygiene optimization. Cognitive behavioral therapy for insomnia (CBT-I). Melatonin where appropriate for circadian-rhythm issues. FDA-approved hypnotics under medical supervision where clinically indicated. Peptide interventions aren't a first-line evidence-based approach to sleep dysfunction.